Welcome to our dedicated page for Inspira Tech SEC filings (Ticker: IINNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Inspira Technologies Oxy B.H.N. Ltd. (IINNW) provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings often include or reference press releases that describe product milestones, regulatory clearances, purchase orders, government-related discussions, and financing transactions.
Through its Form 6-K submissions, Inspira reports developments such as FDA 510(k) clearance and Israeli AMAR certification for the INSPIRA ART100 cardiopulmonary bypass system, government and institutional purchase orders for ART100 systems, and updates on the HYLA real-time blood sensor’s progress toward U.S. Food and Drug Administration submission. Other 6-K filings have covered matters like sales agreement amendments, private placements, and the activation of consulting firms to support business initiatives.
On this page, users can review how Inspira describes its INSPIRA ART platform, ART100 system, VORTX oxygenation technology, INSPIRA Cardi-ART device, and HYLA blood sensor within official filings. These documents outline the development status of each technology, including statements that certain products are still being designed and developed, have not been tested or used in humans, and are not yet approved by regulatory entities.
Stock Titan enhances access to these filings with tools that surface key sections and context from lengthy reports, helping readers quickly locate information on topics such as product regulatory status, capital raising activities, and material agreements. Real-time updates from EDGAR ensure that new Inspira Technologies filings, including future 6-Ks and other forms, appear here as they are submitted, alongside any disclosed information on warrants, purchase orders, or other corporate actions.
Inspira Technologies Oxy B.H.N. Ltd. reported a fully paid $390,000 purchase order for its additive manufacturing electronics (AME) system from a premier Asia-Pacific technological research university focused on quantum computing.
The order was prepaid before shipment and is structured to generate ongoing recurring revenue from consumables and annual service fees. Inspira plans to deliver and deploy the AME system in the coming weeks, along with advanced application training for the university’s quantum research teams.
Inspira Technologies Oxy B.H.N. Ltd. reported a fully paid $390,000 purchase order for its additive manufacturing electronics (AME) system from a premier Asia-Pacific technological research university focused on quantum computing.
The order was prepaid before shipment and is structured to generate ongoing recurring revenue from consumables and annual service fees. Inspira plans to deliver and deploy the AME system in the coming weeks, along with advanced application training for the university’s quantum research teams.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 for Chief Business Officer Yoav Rozanovich. This statement of beneficial ownership, based on the provided data, shows no reported common stock or derivative holdings and records no buy, sell, gift, or option exercise activity.
Inspira Technologies OXY B.H.N. Ltd filed an initial Form 3 for Chief Business Officer Yoav Rozanovich. This statement of beneficial ownership, based on the provided data, shows no reported common stock or derivative holdings and records no buy, sell, gift, or option exercise activity.
Inspira Technologies OXY B.H.N. Ltd. reports the successful commercial delivery and acceptance of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site under a commercial agreement. The customer operates in advanced areas such as quantum computing, quantum networking, integrated photonics, and superconducting systems, where complex integration and extreme miniaturization are critical.
The engagement includes ongoing supply of proprietary consumables and materials, creating a contractual basis for recurring revenue beyond the initial system sale, with added potential from application-specific adaptations as usage grows. Management describes this deployment as tangible commercial execution of Inspira’s AME strategy in a top-tier defense environment and views it as evidence of commercial demand for the platform. Inspira is focused on quantum connectivity hardware while continuing to advance its medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. reports the successful commercial delivery and acceptance of its Additively Manufactured Electronics (AME) system at a Tier-1 U.S. defense customer site under a commercial agreement. The customer operates in advanced areas such as quantum computing, quantum networking, integrated photonics, and superconducting systems, where complex integration and extreme miniaturization are critical.
The engagement includes ongoing supply of proprietary consumables and materials, creating a contractual basis for recurring revenue beyond the initial system sale, with added potential from application-specific adaptations as usage grows. Management describes this deployment as tangible commercial execution of Inspira’s AME strategy in a top-tier defense environment and views it as evidence of commercial demand for the platform. Inspira is focused on quantum connectivity hardware while continuing to advance its medical technology portfolio.
Inspira Technologies Oxy B.H.N. Ltd. has called an Extraordinary General Meeting of shareholders for May 6, 2026, at 12:00 p.m. Israel time in Ra’anana. Shareholders of record at the close of business on April 21, 2026 are entitled to receive notice and vote.
The single proposal asks shareholders to approve changing the company’s name to “QTREX Ltd.”, or a similar name approved by the Israeli Registrar of Companies, and to amend the articles of association accordingly. Approval requires a Simple Majority of votes cast, and the Board unanimously recommends voting in favor.
The materials detail quorum rules, proxy voting for shareholders of record and beneficial owners, and procedures for submitting additional agenda items and position statements under Israeli law. The 6-K also incorporates these meeting materials by reference into several existing Form F-3 and Form S-8 registration statements.
Inspira Technologies Oxy B.H.N. Ltd. has called an Extraordinary General Meeting of shareholders for May 6, 2026, at 12:00 p.m. Israel time in Ra’anana. Shareholders of record at the close of business on April 21, 2026 are entitled to receive notice and vote.
The single proposal asks shareholders to approve changing the company’s name to “QTREX Ltd.”, or a similar name approved by the Israeli Registrar of Companies, and to amend the articles of association accordingly. Approval requires a Simple Majority of votes cast, and the Board unanimously recommends voting in favor.
The materials detail quorum rules, proxy voting for shareholders of record and beneficial owners, and procedures for submitting additional agenda items and position statements under Israeli law. The 6-K also incorporates these meeting materials by reference into several existing Form F-3 and Form S-8 registration statements.
Inspira Technologies Oxy B.H.N. Ltd. filed a report announcing the appointment of Mr. Yoav Rozanovich, age 37, as Chief Business Officer. He previously served as VP Global Customer Success at Nano Dimension Ltd. from February 2021 to April 2026, and as Global Application Engineering Director at Nano Dimension Technologies Ltd. from 2019 to 2021. Inspira plans to enter into its standard indemnification agreement with him on terms similar to those for its other directors and executive officers. This report, including its exhibit, is incorporated by reference into Inspira’s existing registration statements on Form F-3 and Form S-8.
Inspira Technologies Oxy B.H.N. Ltd. filed a report announcing the appointment of Mr. Yoav Rozanovich, age 37, as Chief Business Officer. He previously served as VP Global Customer Success at Nano Dimension Ltd. from February 2021 to April 2026, and as Global Application Engineering Director at Nano Dimension Technologies Ltd. from 2019 to 2021. Inspira plans to enter into its standard indemnification agreement with him on terms similar to those for its other directors and executive officers. This report, including its exhibit, is incorporated by reference into Inspira’s existing registration statements on Form F-3 and Form S-8.
Inspira Technologies OXY B.H.N. Ltd. filed a Form 6-K announcing the appointment of Yoav Rozanovich as Chief Business Officer. The company highlights his international commercial experience in additive manufacturing, advanced electronics, and complex systems integration, including senior roles at Nano Dimension, Stratasys, and Orbotech.
As CBO, he will lead Inspira’s commercial strategy with a focus on near-term revenue execution and scalable, long-term market expansion, particularly around its revenue-generating Additive Manufacturing of Electronics business and new quantum computing connectivity offerings. Inspira continues to develop quantum connectivity solutions for dilution cryostats alongside a dedicated medical technology business unit.
Inspira Technologies OXY B.H.N. Ltd. filed a Form 6-K announcing the appointment of Yoav Rozanovich as Chief Business Officer. The company highlights his international commercial experience in additive manufacturing, advanced electronics, and complex systems integration, including senior roles at Nano Dimension, Stratasys, and Orbotech.
As CBO, he will lead Inspira’s commercial strategy with a focus on near-term revenue execution and scalable, long-term market expansion, particularly around its revenue-generating Additive Manufacturing of Electronics business and new quantum computing connectivity offerings. Inspira continues to develop quantum connectivity solutions for dilution cryostats alongside a dedicated medical technology business unit.
Inspira Technologies OXY B.H.N. Ltd. has begun implementing its AME (Additive Manufactured Electronics) technology with a customer described as one of the world's 10 largest U.S.-based companies. The rollout is underway at a U.S. research and development facility integrated into an advanced corporate technology infrastructure.
The engagement focuses on using Inspira’s AME platform for cryogenic connectivity in quantum computing, addressing critical scaling bottlenecks. Inspira views this as validation of its AME technology, reinforcing a recurring revenue relationship and signaling broader demand from elite technology organizations, while it continues to develop its medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. has begun implementing its AME (Additive Manufactured Electronics) technology with a customer described as one of the world's 10 largest U.S.-based companies. The rollout is underway at a U.S. research and development facility integrated into an advanced corporate technology infrastructure.
The engagement focuses on using Inspira’s AME platform for cryogenic connectivity in quantum computing, addressing critical scaling bottlenecks. Inspira views this as validation of its AME technology, reinforcing a recurring revenue relationship and signaling broader demand from elite technology organizations, while it continues to develop its medical technology portfolio.
Inspira Technologies OXY B.H.N. Ltd. is pivoting into the quantum computing sector, redirecting its recently acquired additive manufactured electronics (AME) platform to solve connectivity bottlenecks inside dilution cryostats. The AME technology, developed with over $200 million of investment, has already shown proof of concept in qubit device integration.
The shift is led by CEO Dagi Ben‑Noon and COO Avi Shabtay, who originally developed the AME technology and previously worked at Nano Dimension, alongside other former Nano Dimension personnel. Inspira plans to keep advancing its INSPIRA ART100 respiratory system and HYLA blood monitoring system under a dedicated medical unit.
The company intends to seek shareholder approval to change its name to QTREX Ltd. and has launched a QTREX website to reflect its focus on quantum connectivity solutions, while continuing commercial discussions in both quantum and medical markets.
Inspira Technologies OXY B.H.N. Ltd. is pivoting into the quantum computing sector, redirecting its recently acquired additive manufactured electronics (AME) platform to solve connectivity bottlenecks inside dilution cryostats. The AME technology, developed with over $200 million of investment, has already shown proof of concept in qubit device integration.
The shift is led by CEO Dagi Ben‑Noon and COO Avi Shabtay, who originally developed the AME technology and previously worked at Nano Dimension, alongside other former Nano Dimension personnel. Inspira plans to keep advancing its INSPIRA ART100 respiratory system and HYLA blood monitoring system under a dedicated medical unit.
The company intends to seek shareholder approval to change its name to QTREX Ltd. and has launched a QTREX website to reflect its focus on quantum connectivity solutions, while continuing commercial discussions in both quantum and medical markets.
Inspira Technologies Oxy B.H.N. Ltd. entered an Asset Purchase Agreement to acquire Nano Dimension Technologies Ltd.’s additive manufacturing electronics and Fabrica businesses, including intellectual property, equipment, inventory, customer contracts and facilities.
The total consideration is up to $12.5 million, with $2.0 million paid in cash at closing and up to $10.5 million in deferred payments over the 12 months following closing, tied to net cash proceeds generated by the acquired platform. Inspira plans to place its existing medical business into a wholly owned subsidiary, which will continue operating independently and is not being sold or discontinued as part of this transaction.
Inspira Technologies Oxy B.H.N. Ltd. entered an Asset Purchase Agreement to acquire Nano Dimension Technologies Ltd.’s additive manufacturing electronics and Fabrica businesses, including intellectual property, equipment, inventory, customer contracts and facilities.
The total consideration is up to $12.5 million, with $2.0 million paid in cash at closing and up to $10.5 million in deferred payments over the 12 months following closing, tied to net cash proceeds generated by the acquired platform. Inspira plans to place its existing medical business into a wholly owned subsidiary, which will continue operating independently and is not being sold or discontinued as part of this transaction.
Inspira Technologies Oxy B.H.N. Ltd. submitted a report describing the termination of two equity financing arrangements: its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The company states that no obligations remain and no further advances will be made under either facility. Management explains that ending these facilities aligns with its goal of maintaining a disciplined capital structure as it prepares for its next strategic phase.
The report also highlights that Inspira is a commercial-stage medical device company focused on advanced respiratory support and blood monitoring, including its FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S., ECMO-related uses outside the U.S., and development of the INSPIRA ART500 and HYLA blood sensor platform.
Inspira Technologies Oxy B.H.N. Ltd. submitted a report describing the termination of two equity financing arrangements: its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The company states that no obligations remain and no further advances will be made under either facility. Management explains that ending these facilities aligns with its goal of maintaining a disciplined capital structure as it prepares for its next strategic phase.
The report also highlights that Inspira is a commercial-stage medical device company focused on advanced respiratory support and blood monitoring, including its FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S., ECMO-related uses outside the U.S., and development of the INSPIRA ART500 and HYLA blood sensor platform.